Fmr LLC Has $100.06 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

FMR LLC raised its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 127.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 767,294 shares of the life sciences company's stock after purchasing an additional 429,723 shares during the period. FMR LLC owned about 0.48% of Illumina worth $100,063,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Bank of New York Mellon Corp boosted its stake in Illumina by 7.2% in the second quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company's stock valued at $317,267,000 after acquiring an additional 204,043 shares during the period. Primecap Management Co. CA increased its position in Illumina by 3.6% in the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company's stock worth $328,158,000 after buying an additional 87,599 shares during the period. Millennium Management LLC lifted its stake in Illumina by 305.0% in the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company's stock valued at $155,067,000 after buying an additional 1,118,747 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of Illumina by 148.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company's stock valued at $137,735,000 after acquiring an additional 631,294 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Illumina by 32.1% during the second quarter. Renaissance Technologies LLC now owns 1,000,318 shares of the life sciences company's stock worth $104,413,000 after acquiring an additional 242,800 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Performance

Shares of NASDAQ:ILMN traded down $2.59 on Thursday, hitting $139.91. 1,393,248 shares of the company were exchanged, compared to its average volume of 2,019,056. Illumina, Inc. has a one year low of $100.08 and a one year high of $156.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The firm has a market capitalization of $22.19 billion, a price-to-earnings ratio of -14.05 and a beta of 1.11. The company's 50 day moving average price is $142.90 and its two-hundred day moving average price is $126.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion for the quarter, compared to analysts' expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. Illumina's quarterly revenue was down 3.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.33 earnings per share. Research analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ILMN shares. Stephens boosted their price target on Illumina from $170.00 to $184.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 12th. Citigroup boosted their price objective on Illumina from $155.00 to $190.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Robert W. Baird raised their target price on Illumina from $124.00 to $139.00 and gave the company a "neutral" rating in a research note on Wednesday, November 6th. TD Cowen upped their price target on shares of Illumina from $166.00 to $177.00 and gave the company a "buy" rating in a report on Tuesday, November 5th. Finally, UBS Group raised their price objective on Illumina from $133.00 to $145.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Illumina has an average rating of "Moderate Buy" and an average price target of $164.00.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.